Skip to main content
. 2020 May 24;8(1):e000696. doi: 10.1136/jitc-2020-000696

Figure 2.

Figure 2

Changes in tumor burden from baseline of the response-evaluable patients in the apatinib continues dosing cohort (A) and the apatinib intermittent dosing cohort (B). Disease burden over time in all enrolled patients in the apatinib continues dosing cohort (C) and the apatinib intermittent dosing cohort (D).